论文部分内容阅读
目的观察纤溶酶序贯蚓激酶联合阿司匹林预防脑梗死复发的临床疗效。方法 73例符合入组要求的脑梗死患者随机分成对照组和治疗组,对照组在急性期静脉纤溶酶治疗7天后单独服用小剂量肠溶阿司匹林,治疗组在纤溶酶治疗结束后联合服用阿司匹林及蚓激酶,随访12个月,观察患者纤维蛋白原水平及神经功能恢复情况,同时记录复发率及出血事件发生率。结果在常规治疗基础上加用小剂量降纤治疗(纤溶酶序贯蚓激酶),改善神经功能缺损方面疗效优于对照组,且能减少梗死复发率。联合使用不增加出血危险及肝肾毒性。结论常规治疗基础上加用小剂量降纤治疗(纤溶酶序贯蚓激酶)能明显提高临床疗效,有效预防缺血性卒中复发,且副作用较小、耐受性好。
Objective To observe the clinical efficacy of fibrinolytic sequential lubridin combined with aspirin in the prevention of recurrent cerebral infarction. Methods Seventy-three patients with cerebral infarction who met the inclusion criteria were randomly divided into control group and treatment group. The control group received low-dose enteric-coated aspirin alone after 7 days of intravenous fibrinolytic therapy. The treatment group was treated with fibrinolytic enzyme Aspirin and lumbrokinase. The patients were followed up for 12 months. The level of fibrinogen and the recovery of neurological function were observed. At the same time, the recurrence rate and the incidence of bleeding events were recorded. Results On the basis of routine treatment, low-dose fibrinolytic therapy (fibrinolytic activity of lumbrokinase) was added to improve the neurological deficit. The curative effect was better than that of the control group, and could reduce the recurrence rate of infarction. Combined use does not increase the risk of bleeding and liver and kidney toxicity. Conclusion The conventional treatment combined with low-dose fibrinolytic therapy (fibrinolytic activity of lumbrokinase) can significantly improve the clinical efficacy and effective prevention of ischemic stroke recurrence, and the side effects of small, well tolerated.